Cellectis Reports Q2 and First Half 2026 Financial Results

Cellectis S.A. reported financial results for the six-month period ended June 30, 2026. Revenues and other income decreased significantly to $14.5 million, compared to $30.2 million in the same period of 2025. This decline was primarily driven by a $16.4 million reduction in collaboration revenue from the AstraZeneca (AZ) Joint Research and Collaboration Agreement, reflecting the level of activities performed during the period. Operating expenses rose to $63.1 million, up from $54.0 million, largely due to increased R&D personnel costs, higher stock-based compensation, and clinical development expenses for the BALLI-01 and NATHALI-01 studies. Despite the higher operating loss, the net loss improved slightly to $39.6 million ($0.39 per share) from $41.9 million ($0.42 per share) in 2025, aided by a $9.2 million net financial gain primarily from favorable foreign exchange effects and fair value measurements of EIB warrants. As of June 30, 2026, Cellectis held $166.8 million in cash, cash equivalents, and fixed-term deposits, which the company believes will fund operations for at least 12 months.